StockData
Biogen Inc. logo

Biogen Inc. (BIIB) stock

BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3056% above fair value
$250.79−0.86 (-0.34%)

Close on Nov 17, 2026Market cap $37.07BP/E 107.2Yield –

Biogen total assets

Total assets on the balance sheet at the end of each period.

Biogen's total assets was $32.05B at Sep 30, 2026. For fiscal 2025 it was $29.44B, up 5.0% from the year before. Over ten years it grew 4.2% a year on average. The highest annual figure on record is $29.44B in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$29.44B+5.0%
FY2024Dec 31, 2024$28.05B+4.5%
FY2023Dec 31, 2023$26.84B+9.3%
FY2022Dec 31, 2022$24.55B+2.8%
FY2021Dec 31, 2021$23.88B-3.0%
FY2020Dec 31, 2020$24.62B-9.6%
FY2019Dec 31, 2019$27.23B+7.7%
FY2018Dec 31, 2018$25.29B+6.9%
FY2017Dec 31, 2017$23.65B+3.4%
FY2016Dec 31, 2016$22.88B+17.3%
FY2015Dec 31, 2015$19.50B+36.3%
FY2014Dec 31, 2014$14.31B+20.7%
FY2013Dec 31, 2013$11.86B+17.1%
FY2012Dec 31, 2012$10.13B+11.9%
FY2011Dec 31, 2011$9.05B+11.8%
FY2010Dec 31, 2010$8.09B-5.4%
FY2009Dec 31, 2009$8.55B+0.9%
FY2008Dec 31, 2008$8.48B–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$32.05B+9.7%
Q2 FY2026Jun 30, 2026$32.09B+13.3%
Q1 FY2026Mar 31, 2026$29.48B+5.2%
Q4 FY2025Dec 31, 2025$29.44B+5.0%
Q3 FY2025Sep 30, 2025$29.21B+3.2%
Q2 FY2025Jun 30, 2025$28.33B+5.7%
Q1 FY2025Mar 31, 2025$28.03B+5.5%
Q4 FY2024Dec 31, 2024$28.05B+4.5%
Q3 FY2024Sep 30, 2024$28.31B+0.4%
Q2 FY2024Jun 30, 2024$26.80B+6.5%
Q1 FY2024Mar 31, 2024$26.57B+8.0%
Q4 FY2023Dec 31, 2023$26.84B+9.3%
Q3 FY2023Sep 30, 2023$28.19B+13.4%
Q2 FY2023Jun 30, 2023$25.16B+0.3%
Q1 FY2023Mar 31, 2023$24.60B+4.2%
Q4 FY2022Dec 31, 2022$24.55B+2.8%
Q3 FY2022Sep 30, 2022$24.85B+4.4%
Q2 FY2022Jun 30, 2022$25.08B+2.5%
Q1 FY2022Mar 31, 2022$23.61B-1.0%
Q4 FY2021Dec 31, 2021$23.88B-3.0%
Q3 FY2021Sep 30, 2021$23.81B-4.5%
Q2 FY2021Jun 30, 2021$24.47B-4.1%
Q1 FY2021Mar 31, 2021$23.85B-8.7%
Q4 FY2020Dec 31, 2020$24.62B-9.6%
Q3 FY2020Sep 30, 2020$24.93B-9.3%
Q2 FY2020Jun 30, 2020$25.51B-3.0%
Q1 FY2020Mar 31, 2020$26.12B-1.2%
Q4 FY2019Dec 31, 2019$27.23B+7.7%
Q3 FY2019Sep 30, 2019$27.48B+7.8%
Q2 FY2019Jun 30, 2019$26.29B+9.7%
Q1 FY2019Mar 31, 2019$26.45B+1.4%
Q4 FY2018Dec 31, 2018$25.29B+6.9%
Q3 FY2018Sep 30, 2018$25.49B+10.5%
Q2 FY2018Jun 30, 2018$23.95B+10.1%
Q1 FY2018Mar 31, 2018$26.09B+23.1%
Q4 FY2017Dec 31, 2017$23.65B+3.4%
Q3 FY2017Sep 30, 2017$23.07B–
Q2 FY2017Jun 30, 2017$21.76B–
Q1 FY2017Mar 31, 2017$21.20B–
Q4 FY2016Dec 31, 2016$22.88B–

More Biogen figures

See a number that looks wrong?